Results of 2024 Annual General Meeting
Released
Released
Announcement PDF
ASX Announcement
Results of 2024 Annual General Meeting
Melbourne, Australia; 26 November 2024: Starpharma (ASX: SPL, US OTC: SPHRY), announces
the details of the resolution and the proxies and votes received in respect of resolutions 2 to 4 at
its Annual General Meeting (AGM) held today in accordance with ASX listing rule 3.13.2 and
section 251AA of the Corporations Act, as set out in the attached proxy and voting summary.
As noted in the AGM, the Chair has exercised discretion to adjourn one item of business until
Friday 29 November 2024, being the vote on the Resolution 1 - Adoption of the Remuneration
Report. This is the result of an offshore custodian needing additional time to amend votes on
behalf of beneficial owners.
Details of the adjourned meeting and voting instructions on Resolution 1 will be released on the
ASX market announcements platform once arrangements are made to reconvene the meeting
for Resolution 1.
About Starpharma
Starpharma ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing
dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve
improved health outcomes and quality of life through the application of our unique dendrimer technology.
Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure,
high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.
Starpharma’s portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets,
preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.
For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.
WE Communications
Hannah Howlett
+61 450 648 064
WE-AUStarPharma@weworldwide.com
Starpharma Holdings Limited
Cheryl Maley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067
Disclosure
This ASX Announcement was
authorised for release by the Chair,
Mr Rob Thomas.
Forward-Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking
terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”,
“potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied
discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance
or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s
and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be
approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding
the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional
analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain
patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and
additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from
those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and
does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or
developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not
necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or
reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise,
representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.
Starpharma Holdings Limited
Annual General Meeting
Tuesday, 26 November 2024
Results of Meeting
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
Resolution details
Resolution
Resolution
Type
1 Adoption of Remuneration Report
Ordinary
2 Re-election of Board endorsed
Director, Ms Lynda Cheng
Ordinary
3 Approval of issue of Performance
Rights to Ms Cheryl Maley
Ordinary
4 Re-insertion of proportional
takeover approval provisions in the
Constitution
Special
Instructions given to validly appointed proxies
Number of votes cast on the poll
Resolution
(as at proxy close)
Proxy's
Against
Discretion
(where applicable)
Result
Carried /
Not Carried
Adjourned
For
Abstain
Resolution has been postponed to the adjourned meeting.
134,007,086
63,595,881
710,114
67.57%
32.07%
0.36%
168,804,658
16,090,364
731,114
90.94%
8.67%
0.39%
195,526,623
903,763
731,114
99.16%
0.46%
0.38%
For
Against
Resolution has been postponed to the adjourned meeting.
136,274,058
64,455,405
67.89%
32.11%
516,406
171,323,724
16,326,326
91.30%
8.70%
1,446,724
199,182,803
996,773
99.50%
0.50%
295,143
Abstain*
896,837
Carried
963,700
Carried
1,446,724
Carried
* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.
Resolution(s) proposed but not put to the meeting
Resolution
Reason for not putting the resolution to the meeting
1 Adoption of Remuneration Report Resolution was not put to the meeting as it has been postponed to the adjourned meeting.
1/1
Share your feedback
Discover